New York Law Journal Recognizes Paul Hastings Life Sciences IP Litigators as New York Trailblazers
New York – The New York Law Journal has named
The trio of Bruce Wexler, who chairs the firm’s Life Sciences practice, Eric Dittmann, global vice chair of the firm's Intellectual Property practice, and IP Litigation Partner Isaac Ashkenazi were noted for having litigated against virtually every generic drug manufacturer.
The New York Law Journal reported on a victory for Boehringer Ingelheim, where Wexler, Dittmann, and Ashkenazi led a team through fact, expert and Markman phases, obtaining six walk-away consent judgments from generics infringing patents relating to Boehringer’s blood thinning drug, Pradaxa.
Regarding the practice of life sciences patent litigation in the future, “The branded versus generic small molecule world will be around for a long time, and will be a part of our business,” said Isaac Ashkenazi. “The biosimilar world is really on its way up and it’s going to be a much larger part of life sciences practices.”
The Trailblazer profile can be read on page 26
The Paul Hastings Life Sciences practice has regularly been honored including:
The firm was namedLife Sciences IP Litigation Firm of the Yearin Managing Intellectual Property’s 2019 Americas Awards.
The firm was named American Lawyer’s2018 Transatlantic IP Team of the Year.
The firm wasnationally rankedby Managing Intellectual Property in Patent Contentious, PTAB Litigation, and Life Sciences.
The firm received top-tiered nationwide rankings fromIAM Patent 1000in the United States, Japan, and South Korea.
In 2018, the firm was named one of Law360’sLife Sciences Practice Groups of the Year.
Isaac Ashkenazi was named aLife Sciences Rising Starby Law360.
At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.